Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Control and Archival of Chromatographic Data – V 2.0

Posted on By

Analytical Method Development: SOP for Control and Archival of Chromatographic Data – V 2.0

Standard Operating Procedure for Control and Archival of Chromatographic Data in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/350/2025
Supersedes SOP/AMD/350/2022
Page No. Page 1 of 12
Issue Date 01/06/2025
Effective Date 03/06/2025
Review Date 01/06/2026

1. Purpose

The purpose of this SOP is to establish a systematic approach for the control, review, and secure archival of chromatographic data generated during analytical method development. This ensures data

integrity, traceability, compliance with cGMP regulations, and supports regulatory inspections and audits.

2. Scope

This SOP applies to all chromatographic techniques such as HPLC, GC, UPLC, and related instruments used for method development in the Analytical Method Development (AMD) laboratory. It covers electronic and printed data, including chromatograms, audit trails, result summaries, and method files.

3. Responsibilities

  • Analytical Scientist: Responsible for correct data acquisition, documentation, and printouts.
  • AMD Reviewer: Verifies compliance with protocols and ensures completeness before archival.
  • QA Representative: Audits archival system for GMP compliance and ensures adherence to data retention timelines.
  • IT Administrator (if applicable): Manages access controls and data backup on CDS (Chromatography Data System).
See also  Analytical Method Development: Selection of HPLC Column and Mobile Phase - V 2.0

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that all chromatographic data is appropriately controlled, reviewed, and archived in accordance with applicable regulatory guidelines such as 21 CFR Part 11 and ALCOA+ principles.

5. Procedure

5.1 Data Acquisition and Labeling

  1. Each chromatographic run must be assigned a unique sequence ID with analyst initials and date.
  2. Ensure method parameters and sample sequence are saved within the CDS and backed up to the server.
  3. Label each chromatogram with project code, sample ID, batch number, and analysis type.

5.2 Printout and Verification

  1. Obtain printouts of chromatograms, system suitability, integration tables, and summary reports.
  2. Verify printouts for legibility, correct date/time stamp, method version, and integration parameters.
  3. Attach all printouts to the analytical worksheet and route for review.

5.3 Data Review and Approval

  1. Reviewer cross-checks retention time, peak area, resolution, and system suitability criteria.
  2. Any deviation from expected chromatographic behavior must be investigated and documented (refer SOP on OOT/OOS).
  3. Upon approval, reviewer signs and dates each page of chromatographic data.
See also  Analytical Method Development: SOP for Capillary Electrophoresis Method Development - V 2.0

5.4 Electronic Data Control

  1. Ensure all raw data files, methods, and reports are saved in the designated secured network path.
  2. CDS software must have access control (username/password) and audit trail enabled.
  3. Do not delete, overwrite, or rename raw data files post-acquisition.

5.5 Data Archival

  1. Archived data includes:
    • Hard copies of chromatograms and supporting printouts
    • Electronic backup on secure server/CD/DVD/cloud as per policy
  2. Use Annexure-1 to catalog all data sets archived for each study/project.
  3. Store physical records in fireproof cabinets with restricted access.

5.6 Retention Period

  1. Maintain chromatographic records for a minimum of 5 years or as per regulatory/market requirements.
  2. For clinical submissions or stability programs, retention period may extend to product shelf life + 1 year.

5.7 Disposal of Archived Data

  1. Upon completion of retention period, initiate controlled destruction using Annexure-2.
  2. Destruction must be approved by QA and logged with date, responsible person, and method (shredding, digital wiping).

6. Abbreviations

  • CDS: Chromatography Data System
  • QA: Quality Assurance
  • HPLC: High Performance Liquid Chromatography
  • GC: Gas Chromatography
  • UPLC: Ultra Performance Liquid Chromatography
See also  Analytical Method Development: Development of Drug Release Profile - V 2.0

7. Documents

  1. Annexure-1: Chromatographic Data Archival Log
  2. Annexure-2: Data Destruction Request and Approval Form

8. References

  • 21 CFR Part 11 – Electronic Records and Signatures
  • ICH Q7 – GMP for Active Pharmaceutical Ingredients
  • WHO Annex 5 – Guidance on Good Data and Record Management Practices
  • MHRA GxP Data Integrity Guidance

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Simran Kaur Dr. Ravi Reddy Dr. Meenal Patil
Designation Analytical Scientist QA Reviewer Head – AMD
Department Analytical Method Development Quality Assurance Analytical Method Development

11. Annexures

Annexure-1: Chromatographic Data Archival Log

Project ID Sample ID Instrument ID Sequence File Storage Location
AMD-350 SMP-8724 HPLC-04 SEQ-HPLC-350A Cabinet A5, Folder 2

Annexure-2: Data Destruction Request and Approval Form

Data ID Type Retention End Date Destruction Method Approved By
CHRO-2020-001 Printed 31/03/2025 Shredding QA Manager

Revision History:

Revision Date Revision No. Details Reason Approved By
01/06/2025 2.0 Aligned with WHO GXP data integrity guidance Annual SOP Review Dr. Meenal Patil
01/05/2022 1.0 Initial Release New SOP QA Head
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Analytical Method Development: SOP for Investigation of Out-of-Trend (OOT) Results – V 2.0
Next Post: Elixir Department: SOP for Risk Assessment During Manufacturing – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2026 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version